Cingulate (CING) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed MAIA Biotechnology (MAIA) over the past year, gaining 27.8% versus a gain of 21.7%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $67.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | MAIA |
|---|---|---|
| Share price | $4.51 | $1.11 |
| Market cap | $67.48M | $68.54M |
| 1-day change | -14.26% | -2.63% |
| YTD return | +3.92% | -27.45% |
| 1-year return | +27.76% | +21.71% |
| EPS (TTM) | $-2.67 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.45M | $-22.40M |
| 52-week high | $11.89 | $3.19 |
| 52-week low | $3.16 | $0.895 |
| Distance from 52-week high | -62.07% | -65.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +370.07% | +981.08% |
| Average volume | 178.82K | 524.29K |
| Shares outstanding | 14.96M | 61.75M |
| Employees | 14 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
CING vs MAIA FAQ
Which is bigger, Cingulate or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $67.48M for Cingulate (CING).
Which stock has performed better over the past year, CING or MAIA?
CING returned +27.76% over the past 12 months, compared with +21.71% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.